• Loading stock data…

biotech news

Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

Saint Herblain (France), September 28, 2022 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the "Company"), a specialty vaccine company, today announced its intention to issue and sell, subject to … [Read more...] about Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

Valneva annonce le lancement d’un projet d’offre globale d’environ $40 millions d’American Depositary Shares et d’actions ordinaires

Saint-Herblain (France), 28 septembre 2022 - Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), soci?t? sp?cialis?e dans les vaccins, annonce aujourd'hui, sous r?serve des conditions de march?, son … [Read more...] about Valneva annonce le lancement d’un projet d’offre globale d’environ $40 millions d’American Depositary Shares et d’actions ordinaires

Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure

WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute … [Read more...] about Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure

Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event

WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver … [Read more...] about Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event

PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX??? for the Prevention of Surgical Site Infections in Abdominal Surgery

Centralized Procedure Allows for Submission of a Single Marketing Application to the European Medicines Agency that, if Approved, Would Allow D-PLEX100 to be Marketed in All EU Member States D-PLEX100 … [Read more...] about PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX??? for the Prevention of Surgical Site Infections in Abdominal Surgery